Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hypertensive crisis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Hypertensive crisis. Displaying page 1 of 1.
    EudraCT Number: 2005-000701-61 Sponsor Protocol Number: BIRD-1 250705 Start Date*: 2005-11-29
    Sponsor Name:University College London
    Full Title: An open label trial of the dual specificity endothelin receptor antagonist bosentan in established scleroderma renal crisis
    Medical condition: Scleroderma renal crisis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005440-98 Sponsor Protocol Number: Start Date*: 2012-04-12
    Sponsor Name:AKH Linz
    Full Title: Double blinded randomised trial for the evaluation of the effectiveness of prophylactic use of sildenafil for the prevention of pulmonary hypertensive crisis after congenital heart surgery
    Medical condition: Ventriculs septal defect, atrioventricular canal with pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10010401 Congenital cardiovascular anomaly therapeutic procedures HLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000727-17 Sponsor Protocol Number: 281274 Start Date*: 2007-08-23
    Sponsor Name:Erasmus MC
    Full Title: Maternal, uteroplacental and fetal haemodynamic effect of Nicardipine in severe pre-eclampsia.
    Medical condition: Hypertensive crisis in patients with severe pre-eclampsia needs to be treated to prevent maternal and fetal complications. The maternal, uteroplacental and fetal haemodynamic respose to antihypert...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040445 Severe pre-eclampsia, antepartum LLT
    9.1 10053094 Doppler echocardiography LLT
    9.1 10045412 Ultrasound Doppler LLT
    9.1 10058179 Hypertensive emergency LLT
    9.1 10038555 Renin LLT
    9.1 10002491 Angiotensin II LLT
    9.1 10053406 Brain natriuretic peptide LLT
    9.1 10001644 Aldosterone LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003200-39 Sponsor Protocol Number: 13/0077 Start Date*: 2014-04-01
    Sponsor Name:University College London
    Full Title: A phase II, single centre, randomised, placebo-controlled, 3-part trial to assess the safety, tolerability and efficacy of Zibotentan in patients with renal disease secondary to scleroderma
    Medical condition: Renal complications of systemic sclerosis (scleroderma renal crisis and chronic kidney disease).
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064848 Chronic kidney disease LLT
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10061087 Connective tissue disorder PT
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10018124 Generalized scleroderma LLT
    16.1 100000004857 10069339 Acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-007180-16 Sponsor Protocol Number: RITIS Start Date*: 2009-05-13
    Sponsor Name:LUMC
    Full Title: INFLUENCE OF B CELL DEPLETION BY MONOCLONAL ANTI-CD20 ANTIBODIES IN SYSTEMIC SCLERODERMA
    Medical condition: systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039710 Scleroderma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-016050-41 Sponsor Protocol Number: E7080-701 Start Date*: 2010-07-29
    Sponsor Name:Eisai Inc.
    Full Title: An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7080 in Combination with Carboplatin + Gemcitabine versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients with Plati...
    Medical condition: Platinum-Sensitive Recurrent Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005376-34 Sponsor Protocol Number: BEV-ONCO2012 Start Date*: 2012-12-20
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Randomized Phase 2 study comparing pathological responses observed on colorectal cancer metastases resected after preoperative treatment combining bevacizumab with FOLFOX or FOLFIRI.
    Medical condition: Resecable Metastatic Cororectal Cancer.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002347-10 Sponsor Protocol Number: E7080-703 Start Date*: 2011-10-14
    Sponsor Name:Eisai Inc.
    Full Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Oral E7080 in Addition to Best Supportive Care (BSC) versus BSC Alone in Patients with Locally Advanced or Metastatic Non-Squamous ...
    Medical condition: Locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) CZ (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 01:11:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA